omeprazole has been researched along with Adverse Drug Event in 14 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin." | 5.40 | Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014) |
| "This phase I, randomized, open-label, two-way crossover trial evaluated the pharmacokinetic effects of lacosamide and omeprazole coadministration." | 2.79 | Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. ( Cawello, W; Fichtner, A; Mueller-Voessing, C, 2014) |
| "Lansoprazole was the drug with the highest number of associated reports (30." | 1.91 | Spontaneous reporting of adverse reactions related to proton pump inhibitors. ( Cicala, G; Cutroneo, P; Dipasquale, V; Laganà, F; Romano, C; Spina, E; Trimarchi, G, 2023) |
| "Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin." | 1.40 | Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Dipasquale, V | 3 |
| Cicala, G | 3 |
| Laganà, F | 3 |
| Cutroneo, P | 3 |
| Trimarchi, G | 3 |
| Spina, E | 3 |
| Romano, C | 3 |
| Neishi, M | 1 |
| Hamano, H | 1 |
| Niimura, T | 1 |
| Denda, M | 1 |
| Yagi, K | 1 |
| Miyata, K | 1 |
| Lin, TJ | 1 |
| Higashionna, T | 1 |
| Goda, M | 1 |
| Zamami, Y | 1 |
| Ishizawa, K | 1 |
| Nawa, H | 1 |
| Andrade, PHS | 1 |
| Lobo, IMF | 1 |
| da Silva, WB | 1 |
| Cawello, W | 1 |
| Mueller-Voessing, C | 1 |
| Fichtner, A | 1 |
| Chen, WC | 1 |
| Li, YD | 1 |
| Chiang, PH | 1 |
| Tsay, FW | 1 |
| Chan, HH | 1 |
| Tsai, WL | 1 |
| Tsai, TJ | 1 |
| Wang, EM | 1 |
| Cheng, JS | 1 |
| Lai, KH | 1 |
| Machado-Alba, JE | 1 |
| Giraldo-Giraldo, C | 1 |
| Moncada-Escobar, JC | 1 |
| Yoshida, S | 1 |
| Nii, M | 1 |
| Date, M | 1 |
| Messinger-Rapport, BJ | 1 |
| Morley, JE | 1 |
| Thomas, DR | 1 |
| Gammack, JK | 1 |
| Higuchi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Omepral® Tablets Mega-study to Investigate the Efficacy on Various Type of Acid Reflux Related Symptoms and QOL, and Epidemiology in Patients With Erosive Esophagitis in Daily Medical Practice[NCT00859287] | 10,703 participants (Actual) | Observational | 2007-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for omeprazole and Adverse Drug Event
| Article | Year |
|---|---|
Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial.
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Cross-Over Studies; Drug Tolerance; Drug-Relate | 2014 |
Effects of omeprazole on symptoms and quality of life in Japanese patients with reflux esophagitis: final results of OMAREE, a large-scale clinical experience investigation.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug-Related Side Effects and Adverse Reactions; Esophagitis, Peptic | 2011 |
12 other studies available for omeprazole and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Clopidogrel; Databases, Factual; Drug-Related S | 2023 |
Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Anesthesia, General; Anti-Bacterial Agents; Ant | 2017 |
Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; F | 2014 |
[Active pharmacosurveillance of patients affiliated to the Colombian general social security/health system].
Topics: Adverse Drug Reaction Reporting Systems; Calcium Channel Blockers; Clopidogrel; Colombia; Diphosphon | 2010 |
Clinical update on nursing home medicine: 2011.
Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delir | 2011 |
Adverse events reporting.
Topics: Abdominal Pain; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Drug-Related Side Effects an | 2007 |